TriSalus Life Sciences (TLSI) Operating Income (2021 - 2026)

TriSalus Life Sciences' Operating Income history runs 6 years deep, the most recent figure standing at -$8.4 million for Q1 2026.

• On a quarterly basis, Operating Income fell 14.76% year-over-year to -$8.4 million in Q1 2026; TTM through Mar 2026 was -$28.0 million, a 11.92% increase from a year earlier, with the FY2025 full-year figure at -$26.9 million, up 25.49% from the prior year.
• Operating Income slipped to -$8.4 million in Q1 2026 per TLSI's latest filing, from -$3.3 million in the prior quarter.
• Across five years, Operating Income topped out at -$288273.0 in Q2 2022 and bottomed at -$18.6 million in Q3 2023.
• The 5-year median for Operating Income is -$8.4 million (2026), against an average of -$8.6 million.
• Across the five-year window, Operating Income soared 63.23% in 2022 and slumped 3866.38% in 2023, its largest moves.
• Year by year, Operating Income stood at -$11.8 million in 2022, then fell by 21.03% to -$14.2 million in 2023, then surged by 46.8% to -$7.6 million in 2024, then jumped by 56.85% to -$3.3 million in 2025, then tumbled by 157.14% to -$8.4 million in 2026.
• Per Business Quant, the three latest TLSI Operating Income figures stand at -$8.4 million (Q1 2026), -$3.3 million (Q4 2025), and -$9.0 million (Q3 2025).